Biosimilars and emerging modalities using novel diol-linked size exclusion columns

Size exclusion chromatography (SEC) is the largest analytical liquid chromatography (LC) market for biotherapeutics and continues to be an important workflow in aggregate analysis of biopharma therapeutic platforms. In this webinar, join Dr. Helen Whitby, senior product manager for biopharmaceuticals LC at Phenomenex, as she explores the applicability of the new diol-link size exclusion column, bioZen™ dSEC-2, for the effective analysis of biosimilars, antibody–drug conjugates (ADCs) and oligonucleotides.

Key learning objectives

• Find out more about SEC
• Explore top tips on how to be successful with ultra-performance liquid chromatography (UPLC) and high-performance liquid chromatography (HPLC) SEC
• Understand more about the analysis of biosimilars by size exclusions
• Learn about SEC nuances for the analysis of emerging modalities

Who should attend?

• Scientists looking to improve their SEC
• Scientists who want to learn more about column selection, specifically for biosimilars and emerging modalities

Certificate of attendance

All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.